Camelot Portfolios LLC Invests $647,000 in Becton, Dickinson and Company $BDX

Camelot Portfolios LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 3,754 shares of the medical instruments supplier’s stock, valued at approximately $647,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Becton, Dickinson and Company by 50.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock worth $18,808,000 after buying an additional 27,581 shares during the last quarter. FORA Capital LLC purchased a new stake in Becton, Dickinson and Company during the 1st quarter worth about $3,458,000. Foster Victor Wealth Advisors LLC purchased a new stake in Becton, Dickinson and Company during the 1st quarter worth about $6,406,000. Finally, GAMMA Investing LLC lifted its holdings in Becton, Dickinson and Company by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock worth $744,000 after buying an additional 748 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Up 2.2%

Shares of BDX opened at $184.59 on Friday. The stock has a fifty day moving average of $188.27 and a two-hundred day moving average of $188.72. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a market capitalization of $52.91 billion, a PE ratio of 33.20, a price-to-earnings-growth ratio of 1.49 and a beta of 0.27. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.Becton, Dickinson and Company’s revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the firm posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is presently 74.82%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on BDX shares. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a research report on Thursday. They set a “sector perform” rating and a $211.00 target price on the stock. Finally, Morgan Stanley lifted their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $213.09.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of the company’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This represents a 19.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Claire Fraser sold 917 shares of the company’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,965 shares of company stock valued at $551,536. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.